Neurocrine Biosciences Inc's Chief Commercial Officer Eric Benevich Sells Company Shares
Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), executed a sale of 2,260 shares in the company on February 8, 2024, as reported in a recent SEC Filing. Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases and disorders.
Over the past year, the insider has sold a total of 5,067 shares of Neurocrine Biosciences Inc and has not made any purchases of the stock.
The insider transaction history for Neurocrine Biosciences Inc indicates a pattern of 53 insider sells and no insider buys over the past year.
On the date of the insider's recent sale, shares of Neurocrine Biosciences Inc were trading at $138.68, resulting in a market capitalization of $13.199 billion.
The stock's price-earnings ratio stands at 55.55, which is above the industry median of 22.12 but below the company's historical median price-earnings ratio.
With the current share price of $138.68 and a GuruFocus Value of $151.32, Neurocrine Biosciences Inc has a price-to-GF-Value ratio of 0.92, indicating that the stock is considered Modestly Undervalued according to the GF Value metric.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor related to the company's past performance, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
